Table 4.
EULAR responses and ACR improvement in RA patients at the end of 24 weeks of tocilizumab therapy
| Case no. | DAS28-ESR | HAQ | CRP (mg/dl) | ESR (mm/h) | Anti-CCP Abs (U/ml) | IgM RF (IU/ml) | SJC28 (SJC66) | TJC28 (TJC68) | EULAR response | ACR improvement |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4.0 | 0.62 | <0.05 | 13 | 342 | 52 | 4 (11) | 7(15) | Moderate | ACR20 |
| 2 | 3.4 | 0.75 | <0.05 | 6 | Negative | Negative | 0 (3) | 9 (11) | Moderate | ACR70 |
| 3 | 2.4 | 0.25 | <0.05 | 6 | 6 | 30 | 0 (0) | 0 (2) | Good | ACR70 |
| 4 | 1.2 | 0.25 | <0.05 | 3 | 124 | Negative | 1 (1) | 0 (0) | Good | ACR70 |
| 5 | 2.2 | 0.25 | <0.05 | 2 | 157 | 157 | 0 (0) | 1 (1) | Good | ACR70 |
| 6 | 8.6 | 3.00 | 6.6 | 112 | 865 | 186 | 20 (40) | 22 (42) | None | Refractory |
| 7 | 3.6 | 0.50 | <0.05 | 20 | 42 | 38 | 1 (1) | 2 (3) | Moderate | ACR50 |
| 8 | 3.6 | 0.50 | <0.05 | 20 | Negative | 29 | 1 (1) | 2 (2) | Moderate | ACR50 |
| 9 | 1.8 | 0.25 | <0.05 | 5 | 224 | 79 | 0 (0) | 1 (1) | Good | ACR70 |
All patients had received tocilizumab for 24 weeks. Data were obtained 24 weeks after starting tocilizumab therapy
RA rheumatoid arthritis, DAS28 disease activity score for 28 joints, HAQ health assessment questionnaire score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, anti-CCPAbs anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, SJC28 swollen joint count in 28 joints, TJC28 tender joint count in 28 joints, EULAR European League Against Rheumatism, ACR American College of Rheumatology